Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,569.77
-2.7697-0.18%
Number of Gainers:2
Number of Losers:5
Number of Flat:- -
PE:- -
High:1,588.44
Open:1,572.59
Low:1,566.72
Close:1,572.54
Volume:49.63M
Turnover:4.82B
Market Cap:1.64T
Float Cap:1.57T

Loading ...

Structure Falls as Investors Await More Obesity Trial Data, Says Jefferies

Reuters
·
Yesterday

Amgen Stock Poised for Worst Day in More than Two Decades

Dow Jones
·
Yesterday

Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback

TIPRANKS
·
Yesterday

Top Midday Decliners

MT Newswires Live
·
Yesterday

GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could be Another Huge Market.

Dow Jones
·
Yesterday

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Yesterday

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Yesterday

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Yesterday

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Yesterday

Structure obesity portfolio updates ‘encouraging,’ says Clear Street

TIPRANKS
·
Yesterday

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

Pfizer CEO Bourla to Speak at Morgan Stanley Global Healthcare Conference Webcast

Reuters
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08